New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder

@article{Eriksson2002NewPO,
  title={New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder},
  author={E. Eriksson and J. Endicott and B. Andersch and J. Angst and K. Demyttenaere and F. Facchinetti and M. Lanczik and S. Montgomery and G. Muscettola and P. O'brien and J. Studd and C. Sundblad and A. Young},
  journal={Archives of Women's Mental Health},
  year={2002},
  volume={4},
  pages={111-119}
}
SummaryPremenstrual dysphoric disorder was discussed by a panel of European researchers. The criteria for diagnosis of the condition, its categorisation as a mental disorder, and its differentiation from depression and premenstrual syndrome are all considered. Data on the treatment of premenstrual dysphoric disorder, using serotonin reuptake inhibitors and other therapies, are reviewed. An algorithm for the treatment of premenstrual dysphoric disorder is proposed. 
A Comprehensive Review of Treatment Options for Premenstrual Syndrome and Premenstrual Dysphoric Disorder
TLDR
Serotoninergic antidepressants have been established as the first-line treatment option for PMDD; however, there are a variety of additional treatment options that should be considered if a patient fails to achieve an adequate therapeutic response with a selective serotonin reuptake inhibitor. Expand
Advances in the diagnosis of premenstrual syndrome and premenstrual dysphoric disorder.
TLDR
The diagnostic criteria for PMS and PMDD is reviewed, some of the more common symptom diaries and other diagnostic tools used to diagnose premenstrual disorders are described, and the challenges inherent in diagnosing PMS are discussed. Expand
Ethinyl Estradiol/Drospirenone for the Treatment of the Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder
TLDR
A combined oral contraceptive pill containing 20 μg of ethinyl estradiol and 3 mg of the progestin drospirenone in a novel dose regimen has demonstrated efficacy for the symptoms of premenstrual dysphoric disorder, a severe form of prewomen's syndrome, with an emphasis on the affective symptoms. Expand
Update on research and treatment of premenstrual dysphoric disorder.
TLDR
Evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms in the week prior to menses. Expand
Estrogens and Other Hormones in the Treatment of Premenstrual Syndromes
TLDR
The role of the female sex hormones in premenstrual symptomatology has long been considered of central importance and is shown in studies of postmenopausal hormone replacement therapy and in a recent animal model of PMS. Expand
Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
TLDR
These guidelines present practical treatment algorithms for the use of SSRIs in women with pure PMDD or severe PMS, PMDD and underlying subsyndromal clinical features of mood or anxiety, or premenstrual exacerbation of a mood/anxiety disorder. Expand
Premenstrual dysphoric disorder amongst Nigerian university students: prevalence, comorbid conditions, and correlates
TLDR
The rate of premenstrual dysphoric disorder in sub-Saharan African women was comparable to that in the western cultures and planning and implementing an effective strategy to manage perimenstrual problems in this region should be an issue of priority. Expand
Premenstrual syndrome
TLDR
Interventions that abolish ovarian cyclicity, including long-acting analogues of gonadotropin-releasing hormone (GnRH) or oestradiol (administered as patches or implants), effectively reduce the symptoms, as can some oral contraceptives. Expand
The Efficacy of Hypericum perforatum (St John’s Wort) for the Treatment of Premenstrual Syndrome
TLDR
Daily treatment with Hypericum perforatum was more effective than placebo treatment for the most common physical and behavioural symptoms associated with PMS, and proinflammatory cytokine levels did not differ significantly between Hypericumperforatum and placebo treatment. Expand
Psychosomatic approaches to obstetrics, gynaecology and andrology
  • M. Lal
  • Medicine
  • Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • 2009
TLDR
Clinical applications of the psychosomatic approach are discussed for various conditions including chronic pelvic pain, eating disorders, tokophobia, post-traumatic stress disorder, depression, menstrual disorders, infertility, bereavement and testicular cancer. Expand
...
1
2
...

References

SHOWING 1-10 OF 83 REFERENCES
Medical management of premenstrual dysphoric disorder.
  • K. Yonkers
  • Medicine
  • The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia
  • 1999
TLDR
Women who suffer from severe dysphoric premenstrual complaints can now be accurately diagnosed and the use of antidepressants that block the serotonin transporter, and the benzodiazepine anxiolytic alprazolam is supported. Expand
Medical management of premenstrual dysphoric disorder.
TLDR
Women who suffer from severe dysphoric premenstrual complaints can now be accurately diagnosed and the use of antidepressants that block the serotonin transporter, and the benzodiazepine anxiolytic alprazolam is supported. Expand
Is premenstrual dysphoric disorder a distinct clinical entity?
TLDR
The consensus of the group was that PMDD is a distinct clinical entity and potential treatments for this disorder can now be evaluated on this basis to meet the clear need for effective therapy. Expand
The role of fluoxetine in the treatment of premenstrual dysphoric disorder.
TLDR
Fluoxetine 20 mg/d is an effective and well-tolerated treatment for women with PMDD, a severe variant of PMS, and intermittent luteal-phase fluoxettine dosing may also be a suitable treatment strategy for selected patients with PM DD. Expand
Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.
  • E. Eriksson
  • Psychology, Medicine
  • International clinical psychopharmacology
  • 1999
TLDR
The observation that the symptoms of PMD may be effectively reduced by SSRIs is of considerable clinical importance since previously no effective treatment for this common condition - apart from those disrupting ovarian cyclicity - has been available. Expand
Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.
TLDR
The comparison of 2 classes of antidepressants strongly favored the serotonergic drug, which effectively reduced symptoms and improved functioning and was well tolerated by women with severe premenstrual syndrome. Expand
Non-antidepressant treatment of premenstrual syndrome.
TLDR
Recent preliminary trials have suggested efficacy for cognitive therapy, light therapy, and tryptophan and future studies of diet recommendations, exercise, relaxation, magnesium, nonsteroidal anti-inflammatory drugs, diuretics, opiate antagonists, and alternative therapies are needed. Expand
Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment: A Randomized Controlled Trial
TLDR
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Expand
Treatment of premenstrual dysphoria with alprazolam. A controlled study.
TLDR
Improved study design, which addressed methodologic flaws of most previous studies of treatment outcome of "premenstrual syndrome" may account, in part, for the ability to demonstrate significant drug/placebo differences. Expand
Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.
TLDR
Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Expand
...
1
2
3
4
5
...